A randomized, comparative, 3-arm, parallel group, open-label, multicenter study of the efficacy and safety of Bravelle™ (purified human FSH) and Repronex® when mixed in the same syringe and administered subcutaneously in continuous or sequential dose ratios to patients (34–40 years) undergoing in-vitro fertilization: interim data
D.C. Marshall, M. Surrey, B. VanVoorhis, D. Kenigsberg, J.H. Check, P. McShane, J. Eisermann, M.D. Scheiber, L.M. Westphal, W.R. Keye JrVolume:
77
Year:
2002
Language:
english
DOI:
10.1016/s0015-0282(02)03036-4
File:
PDF, 29 KB
english, 2002